26 results about "Therapeutic modalities" patented technology

Apparatus and associated methods relate to management of therapeutic digital assets in a non-medical environment. In an illustrative example, non-medical digital asset(s) (NMDAs) may be evaluated relative to one or more therapeutic modalities. A corresponding therapeutic digital asset (TDA) may, for example, be generated for each therapeutically associated NMDA. The TDA may, for example, be traceably associated with corresponding risks and / or risk mitigations. Each TDA may be associated, for example, with a test profile corresponding to a risk and / or risk mitigation. A TDA may be released into a non-medical digital content delivery environment (DCDE), for example. The TDA may, for example, be monitored in the DCDE to maintain verification and / or validation (VV). A change in the DCDE affecting VV of the TDA may, for example, result in deactivation of the TDA in the DCDE. Various embodiments may advantageously permit VV of selected digital assets in a non-medical environment.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and / or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and / or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and / or determine efficacy of a treatment modality.

The present invention belongs to the technical field of sensorineural hearing. Provided is the use of SPTBN1 as a target in the treatment of GJB2-related sensorineural hearing loss. The use comprises: the construction of a stably transfected cell line, wherein: HEK293T cells are cultured using a DMEM culture medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37ºC with 95% air and 5% CO2, and when the cells reach 80%-90% confluence, cell passage is performed; IP-MS analysis, wherein: protein complexes are purified using Protein A / G immunoprecipitation magnetic beads, a portion of the extracted proteins is used as input, and then 2 μg of anti-Cx26 antibody is added to the remaining protein extract, same are gently pipetted and mixed, and incubated on a rotating shaker at 4℃ overnight; immunofluorescence observation of the co-localization of Cx26 and SPTBN1, wherein: a stably transfected cell line expressing WT-Cx26 and Mut-Cx26 is constructed; and co-immunoprecipitation (Co-IP) validation, wherein: a stably transfected cell line expressing WT-Cx26 is constructed. The present invention overcomes the limitations of therapeutic methods, such as the relatively low targeting specificity and short therapeutic time windows associated with full-length protein supplementation via gene therapy, thereby providing new insight into GJB2-related hearing loss, and a new target and a new treatment for same.

The invention discloses an integrated guide control method for a prostate dilation catheter, relates to the technical field of medical treatment, solves the problem of highly integrating two core links of'guide 'and'control' in an operation, and realizes simplification of operation, accuracy of positioning and controllability of mechanical parameters, so that the treatment effect is ensured, and the operation cost is reduced. According to the technical scheme, the method is characterized by comprising the following steps that firstly, preoperative measurement and planning are carried out; 2, a catheter is placed in and initially positioned; 3, integrated guiding and accurate anchoring are carried out; the prostate dilation device has the advantages that the prostate dilation operation is successfully converted from a complex technology which highly depends on experience and equipment to an advanced treatment mode which is standardized, quantitative, minimally invasive and excellent in function protection through unique integrated guide and control design, and revolutionary improvement is brought to multiple dimensions of curative effect, safety, function and efficiency.

Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific anatomical regions (e.g., organs and / or tissue). Notably, the image analysis approaches described herein are not limited to a single particular organ or portion of the body. Instead, they are robust and widely applicable, providing for consistent, efficient, and accurate detection of anatomical regions, including soft tissue organs, in the entire body. In certain embodiments, the accurate identification of one or more such volumes is used to automatically determine quantitative metrics that represent uptake of radiopharmaceuticals in particular organs and / or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and / or determine efficacy of a treatment modality.

The invention belongs to the technical field of medicines, and particularly relates to novel application of polyethylene glycol in preparation of a medicine for treating or reversing pulmonary fibrosis. A new normal form for reversing diseases in a force treatment mode by applying middle-low molecular weight polyethylene glycol (PEG with the molecular weight of 200-3000 Da) to improve extracellular osmotic pressure is put forward and verified for the first time. Through functional verification of cell experiments and animal experiments, the system illustrates that the force treatment activates a mechanical sensitive signal network by inducing alveolar epithelial cell volume compression so as to realize a deep mechanism of EMT (epithelial-mesenchymal transition) molecular cascade reversion. The action path from the physical force to the biological signal provides a brand new theoretical foundation stone for developing a fibrosis treatment strategy based on mechanical microenvironment regulation and control, and PEG300 is a representative preferable embodiment.

Surgical instruments, methods, and software are presented herein that are configured to actuate an end effector to grasp between the pair of jaws, compress tissue during a tissue relaxation time period in which grasped tissue relaxes between the pair of jaws, monitor a motor parameter of the motor during at least a portion of the tissue relaxation time period, extract a mathematical feature of the motor parameter during at least a portion of the tissue relaxation time period, and determine a treatment modality based at least in part on the mathematical feature.

The present disclosure relates to methods for performing minimally invasive anatomical space access, e.g., minimally invasive subretinal access (MISA), in connection with the delivery of therapeutic modalities to an anatomical space of interest, e.g., the subretinal space, and system components adapted to facilitate such delivery.

The invention discloses application of protoflavin and derivatives thereof in preparation of an METTL7B inhibitor, and belongs to the technical field of medical preparations. The invention aims to solve the technical problem of how to inhibit the enzyme activity of METTL7B. To this end, the present application provides a method for inhibiting the enzymatic activity of methyltransferase METTL7B, the method comprising the step of contacting a substance with methyltransferase METTL7B to inhibit the enzymatic activity of methyltransferase METTL7B, the substance is protoflavin, a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate of the pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable modifier thereof. The invention discloses application of protoflavin or derivatives thereof in inhibition of activity of methyltransferase METTL7B and application of protoflavin or derivatives thereof in preparation of drugs for treating cancers for the first time, and provides a new research target and a potential new treatment mode for cancers.

An object of a system according to an embodiment is to share treatment policies and cases of orthodontist clinics and allow patients to find an optimal clinic.SOLUTION: A system according to an embodiment includes a data-aggregating unit, a classifying unit, a searching unit, a posting platform unit, and an crowdfunding unit. The data aggregation unit aggregates the existing data of each orthodontic clinic. The classification unit classifies the data aggregated by the data aggregation unit into cases such as age, treatment style, and secular change. The search unit searches for an orthodontist's office optimal for the patient based on the data classified by the classification unit. The posting platform unit allows the user to post the treatment progress. The crowdfunding department collects funds through crowdfunding by patients who give up correction due to high treatment costs.SELECTED DRAWING: Figure 1

A system and method for targeted neurological treatment using brainwave entrainment therapy with passive treatment that allows for targeted treatment of particular areas of the brain, particular neurological functions, particular neurological states, and combinations of areas, functions, and states. The system and method receive gait parameters for an individual and compare those against a database of historical gait data to determine if an onset neurodegenerative condition is present, and applies a brainwave entrainment therapy responsive to the determination of the condition. The system and method receive a neurological assessment identifying areas of the brain or neurological functions to be treated, select one or more treatment modalities and frequencies, select a treatment regimen, and apply brainwave entrainment using a treatment regimen while the subject engages in dual-task activities selected to stimulate the areas of the brain, neurological functions, or neurological states to be treated, enhanced, or altered.

The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.

Provided herein are compositions and formulations for alleviating problems associated with glaucomatous neurodegeneration and eye-related conditions, including administration of trapoxin (eye drops or SR) or MMP-based therapeutic modalities. Administration of trapoxin leads to elimination of the disease rate-limiting underlying cause associated with loss of neural lineage cells in glaucoma and related conditions.

The utility model provides a cover type physical therapy device, and aims to realize tight fit with the surface of a breast by accurately adjusting the angle of an electrode plate, so that the physical therapy effect is improved. The device mainly comprises a shell, an adjusting mechanism and a physical therapy device. The shell comprises a containing cover and an adjusting channel, and the containing cover is used for containing a physiotherapy area and providing enough space for containing physiotherapy devices; the adjusting channel is arranged above the containing cover, and installation and free adjustment of the adjusting mechanism are facilitated. The adjusting mechanism comprises a linkage pressing piece and an angle adjusting structure, the linkage pressing piece can move up and down in the adjusting channel, and the angle adjusting structure is combined to adjust the angle of the electrode slice. The physical therapy device further comprises an infrared emission source and an infrared isolation cover, through the infrared heating effect, the treatment effect is enhanced, and double treatment modes are provided. The device is simple in structure and convenient to operate, the physical therapy effect can be effectively improved, and comfortable and accurate treatment experience is provided.

The present invention relates to a PROTAC compound for targeted degradation of CDK2, a preparation method therefor and a use thereof, and provides a PROTAC compound that is capable of targeted degradation of CDK2. Compared with existing CDK2 inhibitors, the small-molecule compound prepared by the present invention can effectively induce the degradation of CDK2 protein in MCF-7 cells, exhibits good ability to inhibit the proliferation of MCF-7 cells, demonstrates favorable therapeutic effects against breast cancer, and has the potential to become an effective treatment modality for malignant tumors.

Disclosed are blocking peptides and related methods, formulations, and compositions, pertaining to the field of biomedicine. Based on the regulatory mechanism by which the negative regulator TGF-β modulates the transport and degradation of STING, the use of AP3D1 as a drug target for in vitro screening of blocking agents is provided to identify the S9 regulatory site and the R26 regulatory site of AP3D1. Corresponding blocking peptides targeting the S9 regulatory site and the R26 regulatory site, respectively, were synthesized to specifically inhibit AP3D1-mediated inactivation of STING signaling by tumor microenvironment factors, thereby blocking at least one of the S9 regulatory site and the R26 regulatory site and effectively restricting STING transport and degradation. The blocking peptide can synergize with various treatment modalities, including chemotherapy, radiotherapy, PARP inhibitors, and STING agonists, significantly enhancing cGAS-STING signaling activation in tumors during therapy and achieving more potent antitumor efficacy.

Disclosures herein are directed to methods for classifying and characterizing cancer epithelial cells and analyzing their level of interaction with secondary cell populations in order to identify, modify or otherwise tailor immunotherapy and treatment modalities to a patient. Also disclosed are methods of identifying suitable patient candidates for immunotherapy treatments as well as methods of identifying targets of immunotherapies for the treatment and / or prevention of cancer.

Methods to enhance the computational localization of cardiac arrhythmia sources are provided. A method may include receiving, from a first user, clinical data associated with a clinical case. The clinical data may include a patient anatomic information, diagnostic and / or treatment modalities, treatment parameters, treatment outcome, and medical literature. The clinical case may be indexed based on a first plurality of characteristics associated with the clinical data. The indexing may include associating at least a portion of the clinical data with a computational simulation of cardiac arrhythmia having a second plurality of characteristics matching the first plurality of characteristics. At least a portion of the clinical data associated with the indexed case may be provided to a second user in response to a query from the user. Related systems and articles of manufacture are also provided.

An all-in-one ultrasound therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious ultrasound therapy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures. The ultrasound therapy can include modalities such as histotripsy, hyperthermia / radio-sensitization, HIFU microbubble-enhanced drug delivery, immunotherapy, sonodynamic therapy, and / or neuromodulation.

The present invention concerns new vectorised VEGF isoforms (AAV-VEGFNF) for use in the treatment of a muscular dystrophy, in particular the Duchenne muscular dystrophy (DMD), in particular combined with an ASO-based therapy.

Methods and systems for recording evoked potentials evoked during electrical stimulation of a patient's neural tissue are disclosed. The methods and systems are useful with treatment modalities, such as spinal cord stimulation (SCS). The disclosed methods and system allow for stimulation artifacts to be reduced in, or removed from, the recorded signals. A residual portion of the stimulation artifact can be modeled and subtracted from a recorded signal that includes both artifact and neural response contributions.

Methods to enhance the computational localization of cardiac arrhythmia sources are provided. A method may include receiving, from a first user, clinical data associated with a clinical case. The clinical data may include a patient anatomic information, diagnostic and / or treatment modalities, treatment parameters, treatment outcome, and medical literature. The clinical case may be indexed based on a first plurality of characteristics associated with the clinical data. The indexing may include associating at least a portion of the clinical data with a computational simulation of cardiac arrhythmia having a second plurality of characteristics matching the first plurality of characteristics. At least a portion of the clinical data associated with the indexed case may be provided to a second user in response to a query from the user. Related systems and articles of manufacture are also provided.

Malignant glioma has a poor prognosis, despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant cycles of TMZ. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme which removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation is a known predictor of temozolomide responsiveness; patients with unmethylated MGMT have a poorer prognosis. We employed deactivated Cas9-CRISPR technology to effectively target methylation in the vicinity of the MGMT methylation-specific polymerase chain reaction (MSP) region, as mediated by the catalytic domain of DNA methyltransferase DNMT3A. In doing so, we discovered that the selected dCas9 / CRISPR-mediated methylation of certain regions of MGMT gene sequences can be used to enhance chemosensitivity in malignant glioma cells.